MannKind Corp
NNFN
Company Profile
Business description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Contact
1 Casper Street
DanburyCT06810
USAT: +1 818 661-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
407
Stocks News & Analysis
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks
New pricing model for embattled ASX tech leader
Investor day shows off potentially disruptive pricing model.
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 3.30 | -0.04% |
| CAC 40 | 8,122.03 | 34.61 | 0.43% |
| DAX 40 | 23,882.03 | 188.32 | 0.79% |
| Dow JONES (US) | 47,850.94 | 31.96 | -0.07% |
| FTSE 100 | 9,710.87 | 18.80 | 0.19% |
| HKSE | 25,862.11 | 73.79 | -0.28% |
| NASDAQ | 23,505.14 | 51.04 | 0.22% |
| Nikkei 225 | 50,260.05 | 768.37 | -1.51% |
| NZX 50 Index | 13,468.25 | 47.37 | -0.35% |
| S&P 500 | 6,857.12 | 7.40 | 0.11% |
| S&P/ASX 200 | 8,611.80 | 2.30 | -0.03% |
| SSE Composite Index | 3,878.99 | 3.19 | 0.08% |